GlassScriptPhysician profile
Alfredo Rabassa
NPI 1932184991
$4,660.71
in general payments reported to CMS, 2019-2025
38 companies · $1,303 in 2025
The $1,303 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $594 · 2020: $132 · 2021: $623 · 2022: $805 · 2023: $536 · 2024: $669 · 2025: $1,303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,304 · Education: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,303.94 |
| Education | $203.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,319.20 | 2019-2025 | |
| Janssen Biotech, INC. | $956.62 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $292.52 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Ferring Pharmaceuticals INC. | $267.00 | 2021-2022 | |
| Daiichi Sankyo INC. | $224.16 | 2019 | |
| Lilly USA, LLC | $194.99 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $182.11 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $104.39 | 2021-2025 | |
| Ethicon US, LLC | $95.49 | 2022 | |
| Genzyme Corporation | $91.70 | 2022-2024 | |
| Redhill Biopharma INC. | $84.70 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $76.90 | 2021-2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.54 | 2019-2021 | |
| Qol Medical, LLC | $57.99 | 2023-2025 | Sucraid |
| Ardelyx, INC. | $56.59 | 2024-2025 | Ibsrela |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $45.53 | 2024 | Iqirvo |
| Merck Sharp & Dohme LLC | $44.78 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $43.92 | 2025 | Zenpep |
| Pentax of America, INC. | $43.38 | 2021-2022 | |
| Evofem Biosciences, INC. | $40.77 | 2024-2025 | Phexxi, Solosec, Phexx |
| Shire North American Group INC | $36.39 | 2019 | |
| Nestle Healthcare Nutrition INC. | $33.53 | 2021 | |
| Allergan, INC. | $31.65 | 2020 | |
| Romark Laboratories, Lc | $30.95 | 2020 | |
| Pfizer INC. | $24.20 | 2023 | |
| Evoke Pharma, INC. | $20.43 | 2024 | |
| Pharmacosmos Therapeutics INC. | $19.42 | 2022 | |
| Novo Nordisk INC | $19.31 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $18.92 | 2023 | Dupixent |
| Glaxosmithkline, LLC. | $17.49 | 2019 | |
| Celgene Corporation | $16.78 | 2021 | |
| Vivus LLC | $15.93 | 2025 | Pancreaze |
| Endo Pharmaceuticals INC. | $15.79 | 2019 | |
| Alfasigma USA, INC. | $15.72 | 2020 | |
| Ironwood Pharmaceuticals, INC | $15.46 | 2022 | |
| Janssen Scientific Affairs, LLC | $14.76 | 2019 | |
| Mallinckrodt Hospital Products INC. | $14.42 | 2024 | Terlivaz |
| Ucb, INC. | $14.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfredo Rabassa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.